Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| HCC1395 | Ulixertinib | 0.1 | 0.9402 | 0.01913 |
| HCC1395 | Ulixertinib | 0.1 | 0.7736 | 0.00546 |
| HCC1395 | Ulixertinib | 0.1 | 0.7915 | -0.00876 |
| HCC1395 | Ulixertinib | 0.316227766 | 0.5535 | 0.03407 |
| HCC1395 | Ulixertinib | 0.316227766 | 0.7349 | 0.02285 |
| HCC1395 | Ulixertinib | 0.316227766 | 0.5608 | 0.03541 |
| HCC1395 | Ulixertinib | 1.0 | 0.5301 | 0.05537 |
| HCC1395 | Ulixertinib | 1.0 | 0.6742 | -0.00011 |
| HCC1395 | Ulixertinib | 1.0 | 0.7052 | 0.03466 |
| HCC1395 | Ulixertinib | 3.16227766 | 0.4573 | 0.00979 |
| HCC1395 | Ulixertinib | 3.16227766 | 0.1771 | 0.02277 |
| HCC1395 | Ulixertinib | 3.16227766 | 0.7320 | 0.02414 |
| HCC1395 | Ulixertinib | 10.0 | 0.2962 | 0.04910 |
| HCC1395 | Ulixertinib | 10.0 | 0.1659 | 0.01886 |
| HCC1395 | Ulixertinib | 10.0 | 0.3005 | 0.05553 |
| HCC1395 | Alvocidib | 0.0001 | 1.4079 | -0.01132 |
| HCC1395 | Alvocidib | 0.0001 | 1.0356 | -0.02346 |
| HCC1395 | Alvocidib | 0.0001 | 0.9613 | -0.01557 |
| HCC1395 | Alvocidib | 0.000316227766017 | 1.2746 | 0.00082 |
| HCC1395 | Alvocidib | 0.000316227766017 | 0.8649 | 0.00977 |
| HCC1395 | Alvocidib | 0.000316227766017 | 0.7796 | 0.00635 |
| HCC1395 | Alvocidib | 0.001 | 0.9946 | 0.00582 |
| HCC1395 | Alvocidib | 0.001 | 0.9236 | -0.01090 |
| HCC1395 | Alvocidib | 0.001 | 0.6505 | 0.01023 |
| HCC1395 | Alvocidib | 0.00316227766017 | 0.8184 | 0.02673 |